排序方式: 共有5条查询结果,搜索用时 118 毫秒
1
1.
Summary. Results of assays of recombinant FVIII concentrates have been reviewed over a 10-year period. Initially there was wide variability between laboratories but this was minimised by the development of standardised assay methodology, in particular the use of haemophilic plasma for pre-dilution and 1% albumin in assay buffers. Using this standardised methodology and concentrate standards, there were no major diferences in potency between one-stage, two-stage, and chromogenic assays on the two full-length recombinant FVIII concentrates. However, using a plasma standard, the chromogenic method gave much higher potencies than the one-stage method on the same concentrates, and this explains a similar discrepancy found in patients' post-infusion samples after injection of recombinant concentrates. It is suggested that concentrate standards be used for such post-infusion samples in order to minimise this discrepancy. 相似文献
2.
3.
S. RAUT R. E. MERTON P. RIGSBY† L. MUSZBEK‡ R. SEITZ§ R. A. S. ARIËNS¶ T. W. BARROWCLIFFE A. ICHINOSE ON BEHALF OF THE ISTH/SSC FACTOR XIII SUBCOMMITTEE THE FACTOR XIII STANDARDIZATION WORKING PARTY 《Journal of thrombosis and haemostasis》2007,5(9):1923-1929
BACKGROUND: An international collaborative study, involving 23 laboratories, was carried out, under the auspices of the FXIII Standardization Working Party (SWP), to calibrate the 1st International Standard (IS) for factor XIII (FXIII) plasma. METHODS: Potency estimates for the proposed candidate FXIII plasma (preparation Y: NIBSC code 02/206) were calculated relative to locally collected normal plasma pools (pool N), for both FXIII activity and antigen levels. RESULTS: Estimates of FXIII activity potency for preparation Y showed good agreement between laboratories, with an interlaboratory geometric coefficient of variation (GCV) of 11.5% and a mean value of 0.91 U mL(-1). Furthermore, there was a negligible difference in potencies by two commercially available methods, the potencies differing only by approximately 1%. Estimates of FXIII antigen (A(2)B(2) complex) potency for preparation Y showed good agreement between laboratories, with an interlaboratory GCV of 16.3% and a mean value of 0.93 U mL(-1). Accelerated degradation studies showed that the proposed standard is very stable, with a predicted loss of activity (and antigen) per year of< 0.06% at the recommended storage temperature of -20 degrees C. CONCLUSIONS: The suitability and potency of preparation Y were considered by the participants, members of the ISTH/SSC FXIII Subcommittee, the Scientific and Standardization Committee and the SWP. Following their approval, preparation Y was proposed to and accepted by the Expert Committee on Biological Standardization of the World Health Organization to be the 1st IS for FXIII plasma with an activity potency of 0.91 IU per ampoule and an antigen potency of 0.93 IU per ampoule. 相似文献
4.
5.
Der Einfluß von Prolaktin und Spermin auf den Zinkgehalt menschlicher Spermatozoen
In einer experimentellen Studie wurde der Einfluß von physiologischen Dosen o-Prolaktin (0–10 ng) und Spermin (0–2 mg) auf den intracellularen Zinkgehalt menschlicher Spermatozoen untersucht. Es ergab sich eine negative Korrelation des Zinkgehaltes zu der Prolaktin- und Spermin-Konzentration. 相似文献
In einer experimentellen Studie wurde der Einfluß von physiologischen Dosen o-Prolaktin (0–10 ng) und Spermin (0–2 mg) auf den intracellularen Zinkgehalt menschlicher Spermatozoen untersucht. Es ergab sich eine negative Korrelation des Zinkgehaltes zu der Prolaktin- und Spermin-Konzentration. 相似文献
1